1 Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer144, 1941-1953, doi:10.1002/ijc.31937 (2019).
2 Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin68, 394-424, doi:10.3322/caac.21492 (2018).
3 Hashibe, M. et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst99, 777-789, doi:10.1093/jnci/djk179 (2007).
4 Mehanna, H. et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region. Head Neck35, 747-755, doi:10.1002/hed.22015 (2013).
5 Ferris, R. L. et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med375, 1856-1867, doi:10.1056/NEJMoa1602252 (2016).
6 Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet394, 1915-1928, doi:10.1016/S0140-6736(19)32591-7 (2019).
7 Tong, C. C., Kao, J. & Sikora, A. G. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol Res54, 266-274, doi:10.1007/s12026-012-8306-6 (2012).
8 Chen, S. M. Y. et al. Tumor immune microenvironment in head and neck cancers. Mol Carcinog, doi:10.1002/mc.23162 (2020).
9 Seliger, B. Strategies of tumor immune evasion. BioDrugs19, 347-354, doi:10.2165/00063030-200519060-00002 (2005).
10 Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell144, 646-674, doi:10.1016/j.cell.2011.02.013 (2011).
11 Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell100, 57-70, doi:10.1016/s0092-8674(00)81683-9 (2000).
12 Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science324, 1029-1033, doi:10.1126/science.1160809 (2009).
13 Warburg, O., Wind, F. & Negelein, E. THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol8, 519-530, doi:10.1085/jgp.8.6.519 (1927).
14 Bonomo, P. et al. What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging45, 2122-2138, doi:10.1007/s00259-018-4065-5 (2018).
15 Cascone, T. et al. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab27, 977-987.e974, doi:10.1016/j.cmet.2018.02.024 (2018).
16 Li, Z. & Zhang, H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci73, 377-392, doi:10.1007/s00018-015-2070-4 (2016).
17 Sattler, U. G. et al. Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol94, 102-109, doi:10.1016/j.radonc.2009.11.007 (2010).
18 Carvalho, K. C. et al. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo)66, 965-972, doi:10.1590/s1807-59322011000600008 (2011).
19 Kimmelman, A. C. Metabolic Dependencies in RAS-Driven Cancers. Clin Cancer Res21, 1828-1834, doi:10.1158/1078-0432.CCR-14-2425 (2015).
20 Tateishi, K. et al. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res22, 4452-4465, doi:10.1158/1078-0432.CCR-15-2274 (2016).
21 Liu, Q. P., Luo, Q., Deng, B., Ju, Y. & Song, G. B. Stiffer Matrix Accelerates Migration of Hepatocellular Carcinoma Cells through Enhanced Aerobic Glycolysis Via the MAPK-YAP Signaling. Cancers (Basel)12, doi:10.3390/cancers12020490 (2020).
22 Xie, Y. et al. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). Mol Med Rep19, 783-791, doi:10.3892/mmr.2018.9713 (2019).
23 Muller, P. A. & Vousden, K. H. p53 mutations in cancer. Nat Cell Biol15, 2-8, doi:10.1038/ncb2641 (2013).
24 DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab7, 11-20, doi:10.1016/j.cmet.2007.10.002 (2008).
25 Semenza, G. L. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev20, 51-56, doi:10.1016/j.gde.2009.10.009 (2010).
26 Jones, R. G. & Thompson, C. B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev23, 537-548, doi:10.1101/gad.1756509 (2009).
27 Chang, C. H. et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell162, 1229-1241, doi:10.1016/j.cell.2015.08.016 (2015).
28 Justus, C. R., Sanderlin, E. J. & Yang, L. V. Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment. Int J Mol Sci16, 11055-11086, doi:10.3390/ijms160511055 (2015).
29 Salazar-Roa, M. & Malumbres, M. Fueling the Cell Division Cycle. Trends Cell Biol27, 69-81, doi:10.1016/j.tcb.2016.08.009 (2017).
30 Eriksson, M. et al. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism. Mol Cell Biol37, doi:10.1128/MCB.00328-17 (2017).
31 Fischer, K. et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood109, 3812-3819, doi:10.1182/blood-2006-07-035972 (2007).
32 Doherty, J. R. & Cleveland, J. L. Targeting lactate metabolism for cancer therapeutics. J Clin Invest123, 3685-3692, doi:10.1172/JCI69741 (2013).
33 Hirschhaeuser, F., Sattler, U. G. & Mueller-Klieser, W. Lactate: a metabolic key player in cancer. Cancer Res71, 6921-6925, doi:10.1158/0008-5472.CAN-11-1457 (2011).
34 Gatenby, R. A., Gawlinski, E. T., Gmitro, A. F., Kaylor, B. & Gillies, R. J. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res66, 5216-5223, doi:10.1158/0008-5472.CAN-05-4193 (2006).
35 Rizza, P., Moretti, F. & Belardelli, F. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity43, 204-209, doi:10.3109/08916930903510880 (2010).
36 Ferrantini, M., Capone, I. & Belardelli, F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie89, 884-893, doi:10.1016/j.biochi.2007.04.006 (2007).
37 Ma, H. et al. Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma. Br J Cancer120, 317-330, doi:10.1038/s41416-018-0352-y (2019).
38 Shi, Y. Regulatory mechanisms of PD-L1 expression in cancer cells. Cancer Immunol Immunother67, 1481-1489, doi:10.1007/s00262-018-2226-9 (2018).
39 Provance, O. K. & Lewis-Wambi, J. Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer. Breast Cancer Res21, 59, doi:10.1186/s13058-019-1140-1 (2019).
40 Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell139, 871-890, doi:10.1016/j.cell.2009.11.007 (2009).
41 Inman, G. J. Switching TGFβ from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev21, 93-99, doi:10.1016/j.gde.2010.12.004 (2011).
42 Hua, W., Ten Dijke, P., Kostidis, S., Giera, M. & Hornsveld, M. TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. Cell Mol Life Sci77, 2103-2123, doi:10.1007/s00018-019-03398-6 (2020).
43 Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol20, 7-24, doi:10.1038/s41577-019-0210-z (2020).
44 Deberardinis, R. J., Sayed, N., Ditsworth, D. & Thompson, C. B. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev18, 54-61, doi:10.1016/j.gde.2008.02.003 (2008).
45 Gottfried, E. et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood107, 2013-2021, doi:10.1182/blood-2005-05-1795 (2006).
46 Thommen, D. S. & Schumacher, T. N. T Cell Dysfunction in Cancer. Cancer Cell33, 547-562, doi:10.1016/j.ccell.2018.03.012 (2018).
47 Fridman, W. H. et al. B cells and cancer: To B or not to B? J Exp Med218, doi:10.1084/jem.20200851 (2021).
48 Jaillon, S. et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer20, 485-503, doi:10.1038/s41568-020-0281-y (2020).
49 Olingy, C. E., Dinh, H. Q. & Hedrick, C. C. Monocyte heterogeneity and functions in cancer. J Leukoc Biol106, 309-322, doi:10.1002/JLB.4RI0818-311R (2019).
50 Fabregat, A. et al. Reactome pathway analysis: a high-performance in-memory approach. BMC Bioinformatics18, 142, doi:10.1186/s12859-017-1559-2 (2017).